FDA Clearance Tracker · K181329
EliA B2-Glycoprotein I IgA Immunoassay, EliA Cardiolipin IgA Immunoassay
Last checked: Nov 20, 2026Latest source record: Jun 25, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jun 25, 2018
Substantially Equivalent
Time to decision
38 days
Received May 18, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K181329
- Device name
- EliA B2-Glycoprotein I IgA Immunoassay, EliA Cardiolipin IgA Immunoassay
- Applicant
- Phadia AB
- Applicant location
- Uppsala, SE
- Received
- May 18, 2018
- Decided
- Jun 25, 2018
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5660
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MSV. The earliest in FDA's data is K970551, decided Jun 24, 1997.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K181329
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Phadia AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- EliA CTD 13 Screen510(k)
K253367 · Decided Jun 25, 2026 · 268 days after receipt
Device type: Extractable Antinuclear Antibody, Antigen And Control (LLL) · Laboratory Medicine & Pathology
K212181 · Decided Aug 3, 2022 · 386 days after receipt
Device type: System, Test, Radioallergosorbent (Rast) Immunological (DHB) · Laboratory Medicine & Pathology
- EliA Ro52, EliA Ro60510(k)
K210902 · Decided Jul 27, 2022 · 488 days after receipt
Device type: Antinuclear Antibody, Antigen, Control (LKJ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.